Opitor-0 is a potent and selective inhibitor of the mitochondrial GTPase Optic atrophy protein 1 (OPA1) with an IC50 of approximately 3 µM. In cellular studies, Opitor-0 disrupts OPA1 oligomer stability, leading to mitochondrial fragmentation and remodeling of mitochondrial cristae. These structural changes facilitate the release of Cytochrome c from mitochondria into the cytosol, triggering apoptotic signaling. The compound exhibits significant pro-apoptotic and antitumor effects in cancer cell models. Importantly, Opitor-0 demonstrates strong synergistic activity with Bcl-2 inhibitors such as ABT-737 and Venetoclax, enhancing tumor cell death. These results suggest that Opitor-0 effectively targets mitochondrial dynamics and apoptosis pathways in cancer cells.
